Switching To Gilenya® (Fingolimod) From Standard Interferon Offers Sustained Freedom From Disease Activity For People With Relapsing Remitting MS
Two new analyses from the pivotal Phase III TRANSFORMS study presented at the European Neurological Society (ENS) have shown early and sustained improvements in disease activity in patients who were switched from an interferon to Gilenya® (fingolimod). Improvements were seen within 12 months of the switch and were sustained up to 4.5 years, confirming the long term effectiveness of once daily pill fingolimod... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 12, 2013 Category: Consumer Health News Tags: Multiple Sclerosis Source Type: news
Switching to Novartis drug Gilenya
Two new analyses from the Phase III TRANSFORMS study presented at the 23rd meeting of the European Neurological Society (ENS) in Barcelona, demonstrated how Novartis' Gilenya® (fingolimod) was effective against all four key measures of disease activity in multiple sclerosis (MS) - brain volume loss, lesion activity (measured by magnetic resonance imaging - MRI), relapse rates and disability progression. Improvements were seen in patients who switched from standard interferon (interferon beta-1a) treatment to Gilenya within 12 months of the switch and up to the end of the 4.5 year extension study. (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 11, 2013 Category: Drugs & Pharmacology Source Type: news
European Neurological Society meeting review part 1
A review of topics covered at the NNS meeting in Barcelona includes birth outcomes in fathers with MS, predictive possibilities of MRI, teriflunomide (Aubagio) and liver injury, alemtuzumab (Lemtrada) and infections, BG-12 (Tecfidera) in people recently diagnosed, and switching to fingolimod (Gilenya).
NeuroSens
Latest MS research updates (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - June 9, 2013 Category: Neurology Source Type: news
European Neurological Society meeting review
A review of topics covered at the NNS meeting in Barcelona includes birth outcomes in fathers with MS, predictive possibilities of MRI, teriflunomide (Aubagio) and liver injury, alemtuzumab (Lemtrada) and infections, BG-12 (Tecfidera) in people recently diagnosed, and switching to fingolimod (Gilenya).
NeuroSens
Latest MS research updates (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - June 9, 2013 Category: Neurology Source Type: news
Fingolimod (Gilenya) study
The makers of fingolimod report their presentations at the ENS meeting in Barcelona that show the drug reduced signs of disease activity - brain volume loss, MRI lesion activity, relapse rates and disability progression - in people who switched from beta interferon.
Novartis press release
Fingolimod (Gilenya) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - June 9, 2013 Category: Neurology Source Type: news
New data shows Gilenya benefited multiple sclerosis
New data will be presented at the 23rd meeting of the European Neurological Society (ENS) that show how Novartis' Gilenya® (fingolimod), the first once-daily oral therapy approved to treat people with relapsing multiple sclerosis (RMS), positively impacted the key measures for multiple sclerosis (MS) - relapse rates, brain volume loss, lesions and disability progression. Improving these key measures led to favourable clinical outcomes. (Source: Pharmacy Europe)
Source: Pharmacy Europe - June 7, 2013 Category: Drugs & Pharmacology Source Type: news
Novartis says study shows Gilenya benefits patients with MS
ZURICH (Reuters) - Novartis said studies show its Gilenya drug helped keep patients with multiple sclerosis free of the disease. (Source: Reuters: Health)
Source: Reuters: Health - June 5, 2013 Category: Consumer Health News Tags: healthNews Source Type: news
New data shows Novartis MS drug improves four key symptoms of disease
A study into Novartis' Gilenya (fingolimod) for the treatment of multiple sclerosis (MS) showed that it positively impacted on the key measures for MS: relapse rates, brain volume loss, lesions and disability progression. (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - June 4, 2013 Category: Pharmaceuticals Source Type: news
Fingolimod and blood disorder
Fingolimod (Gilenya) has been added to the US drug regulator's watch list due to reports of hemophagocytic syndrome - a rare blood disorder. Being on the list doesn't affect availability of fingolimod but means that the FDA will investigate whether there is a link between adverse event and the medication.
Medscape
(requires registration)
Fingolimod (Gilenya) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - May 5, 2013 Category: Neurology Source Type: news
Tecfidera (dimethyl fumarate) approved in US
Tecfidera (BG12) has been approved by the FDA, the American drug regulator, making it the third oral disease modifying drug for relapsing MS to be licensed in the USA after fingolimod (Gilenya) and teriflunomide (Aubagio).
FDA
National MS Society (USA)
MedPage Today
BG12 (Tecfidera) - drugs in development (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - March 27, 2013 Category: Neurology Source Type: news
Drug research from the AAN meeting
Another round up of information presented at the recent AAN (American Academy of Neurology) meeting about disease modifying drugs - includes fingolimod, teriflunomide, pegylated interferon, glatiramer acetate and a combination treatment.
MedPage Today
MS research updates (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - March 27, 2013 Category: Neurology Source Type: news
Gilenya® (Fingolimod) Demonstrates Consistent Benefits In Reduction Of Relapses And Brain Volume Loss In Relapsing-Remitting Multiple Sclerosis
Data presented at the 65th annual meeting of the American Academy of Neurology (AAN) show Gilenya® (fingolimod), the first and only once-daily oral therapy reimbursed to treat highly active relapsing-remitting multiple sclerosis (RRMS), significantly and consistently reduced the rate of brain volume loss and reduced relapse rates compared to interferon beta-1a IM or placebo.(1,2,4) The new data add to the growing body of evidence for fingolimod regarding its early efficacy benefits and long-term safety profile... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - March 25, 2013 Category: Consumer Health News Tags: Multiple Sclerosis Source Type: news
Fingolimod (Gilenya)
Reanalysis of previous study results show that fingolimod reduced the rate of brain volume loss by about a third compared to Avonex or placebo, that the overall reduction in relapse rate was also demonstrated across subgroups such as gender, age, and disease activity, and that no further safety concerns were identified in a two year extension study. Results presented at the AAN (American Academy of Neurology) meeting.
Novartis press release
Bloomberg
Fingolimod (Gilenya) - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - March 21, 2013 Category: Neurology Source Type: news
Getting to the Bottom of Intestinal Inflammation and Cancer
One of the dangers of inflammatory bowel disease (IBD) is the risk of developing intestinal cancers, such as colorectal cancer. Results from a recent study suggest that fingolimod, a drug already approved to treat multiple sclerosis, could decrease or possibly stop the progression of IBD-related cancers. Using a mouse model, researchers showed that increased production of an enzyme causes intestinal cells to produce more molecules that trigger intestinal inflammation and cancer. Giving fingolimod to the mice decreased these activities. The scientists are planning more experiments to understand the link between inflammatory...
Source: NIGMS Biomedical Beat - February 21, 2013 Category: Research Source Type: news
